Compare SUNS & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SUNS | NKTX |
|---|---|---|
| Founded | 2023 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.2M | 132.8M |
| IPO Year | N/A | 2020 |
| Metric | SUNS | NKTX |
|---|---|---|
| Price | $9.30 | $2.01 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $13.00 | ★ $13.25 |
| AVG Volume (30 Days) | 99.5K | ★ 873.9K |
| Earning Date | 03-05-2026 | 03-25-2026 |
| Dividend Yield | ★ 12.90% | N/A |
| EPS Growth | ★ 1112.46 | N/A |
| EPS | ★ 1.09 | N/A |
| Revenue | ★ $19,384,703.00 | N/A |
| Revenue This Year | $165.88 | N/A |
| Revenue Next Year | $46.38 | N/A |
| P/E Ratio | $8.52 | ★ N/A |
| Revenue Growth | ★ 2540.16 | N/A |
| 52 Week Low | $7.80 | $1.31 |
| 52 Week High | $12.35 | $2.74 |
| Indicator | SUNS | NKTX |
|---|---|---|
| Relative Strength Index (RSI) | 44.49 | 42.66 |
| Support Level | $9.08 | $1.91 |
| Resistance Level | $9.54 | $2.27 |
| Average True Range (ATR) | 0.20 | 0.14 |
| MACD | 0.02 | -0.05 |
| Stochastic Oscillator | 40.74 | 8.70 |
Sunrise Realty Trust Inc is a real estate investment trust company. It is focus on originating CRE debt investments and providing capital to high-quality borrowers and sponsors with transitional business plans collateralized by CRE assets with opportunities for near-term value creation, as well as recapitalization opportunities. It intends to create a diversified investment portfolio, targeting investments in senior mortgage loans, mezzanine loans, whole loans, B-notes, CMBS and debt-like preferred equity securities across CRE asset classes and investment mix to include high quality multi-family, condominiums, retail, office, hospitality, industrial, mixed use and specialty-use real estate.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.